These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 34289749)

  • 21. Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens.
    Chen SC; Quartino A; Polhamus D; Riggs M; French J; Wang X; Vadhavkar S; Smitt M; Hoersch S; Strasak A; Jin JY; Girish S; Li C
    Br J Clin Pharmacol; 2017 Dec; 83(12):2767-2777. PubMed ID: 28733983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and pharmacokinetics of a new biosimilar trastuzumab (HL02): a Phase I bioequivalence study in healthy Chinese men.
    Zhang H; Liu T; Wu M; Wei H; Li C; Li X; Liu J; Chen H; Ding Y; Liu L
    Expert Opin Biol Ther; 2022 Feb; 22(2):179-186. PubMed ID: 33616478
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer.
    Rugo HS; Pennella EJ; Gopalakrishnan U; Hernandez-Bronchud M; Herson J; Koch HF; Loganathan S; Deodhar S; Marwah A; Manikhas A; Bondarenko I; Mukhametshina G; Nemsadze G; Parra JD; Abesamis-Tiambeng MLT; Baramidze K; Akewanlop C; Vynnychenko I; Sriuranpong V; Mamillapalli G; Roy S; Yanez Ruiz EP; Barve A; Fuentes-Alburo A; Waller CF
    Breast Cancer Res Treat; 2021 Jul; 188(2):369-377. PubMed ID: 34125340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparative phase III clinical study to evaluate efficacy and safety of TrastuRel™ (biosimilar trastuzumab) and innovator trastuzumab in patients with metastatic human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer.
    Apsangikar P; Chaudhry S; Naik M; Deoghare S; Joseph J
    Indian J Cancer; 2017; 54(4):664-668. PubMed ID: 30082554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study.
    Kolberg HC; Colleoni M; Demetriou GS; Santi P; Tesch H; Fujiwara Y; Tomasevic Z; Hanes V
    Drug Saf; 2020 Mar; 43(3):233-242. PubMed ID: 31927716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Total pathological complete response versus breast pathological complete response in clinical trials of reference and biosimilar trastuzumab in the neoadjuvant treatment of breast cancer.
    Stebbing J; Baranau Y; Manikhas A; Lee SJ; Thiruchelvam P; Leff D; Esteva FJ
    Expert Rev Anticancer Ther; 2018 Jun; 18(6):531-541. PubMed ID: 29580109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of trastuzumab and its efficacy and safety in HER2-positive cancer patients.
    Luo X; Wang N; Xing Y; Gao X; Yu Y; Liu T; Jiang S; Dong M
    Cancer Chemother Pharmacol; 2024 Nov; 94(5):721-732. PubMed ID: 39177768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Appropriate use of trastuzumab in Lazio Region: therapeutic scenarios and estimation of possible savings for the Regional Health Service.].
    Belleudi V; Rosa AC; Musicco F; Marchetti P; Martini N; Andriani A; Calamia T; Addis A
    Recenti Prog Med; 2019 Dec; 110(12):604-614. PubMed ID: 31909763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of the Molecular Mechanism of Action of SB3, a Trastuzumab Biosimilar.
    Paek K; Kim GW; Ahn SY; Lim JH; Jung D; Kim S; Lee JH
    BioDrugs; 2019 Dec; 33(6):661-671. PubMed ID: 31549311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional and Nonclinical Similarity of ABP 980, a Biosimilar of Trastuzumab.
    Jassem S; Wang W; Sweet H; Manoukian R; Chow V; Kanakaraj P; Hutterer KM; Kuhns S; Foltz IN; Chen Q; Ferbas J; McBride HJ
    Pharm Res; 2019 Nov; 36(12):177. PubMed ID: 31696314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Charge variant analysis of proposed biosimilar to Trastuzumab.
    Dakshinamurthy P; Mukunda P; Prasad Kodaganti B; Shenoy BR; Natarajan B; Maliwalave A; Halan V; Murugesan S; Maity S
    Biologicals; 2017 Mar; 46():46-56. PubMed ID: 28087106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
    Al-Saden N; Lam K; Chan C; Reilly RM
    Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study.
    Kirschbrown WP; Wynne C; Kågedal M; Wada R; Li H; Wang B; Nijem I; Badovinac Crnjevic T; Gasser H; Heeson S; Eng-Wong J; Garg A
    J Clin Pharmacol; 2019 May; 59(5):702-716. PubMed ID: 30570763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I dose-escalation and bioequivalence study of a trastuzumab biosimilar in healthy male volunteers.
    Wisman LA; De Cock EP; Reijers JA; Kamerling IM; Van Os SH; de Kam ML; Burggraaf J; Voortman G
    Clin Drug Investig; 2014 Dec; 34(12):887-94. PubMed ID: 25377592
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment.
    Baker JHE; Kyle AH; Reinsberg SA; Moosvi F; Patrick HM; Cran J; Saatchi K; Häfeli U; Minchinton AI
    Clin Exp Metastasis; 2018 Oct; 35(7):691-705. PubMed ID: 30196384
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical applications of trastuzumab in the management of HER-2-positive breast cancer.].
    Del Mastro L; De Laurentiis M
    Recenti Prog Med; 2019 Dec; 110(12):594-603. PubMed ID: 31909762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanism of action of the trastuzumab biosimilar CT-P6.
    Jeong SA; Choi JM; Park JM; Lee JY; Lee SJ; Lee SY; Lee SY; Park YA; Jeong HJ; Song YC; Kim SH; Chang SJ
    Expert Opin Biol Ther; 2019 Oct; 19(10):1085-1095. PubMed ID: 30541352
    [No Abstract]   [Full Text] [Related]  

  • 38. Pharmacokinetic Bioequivalence, Safety, and Immunogenicity of DMB-3111, a Trastuzumab Biosimilar, and Trastuzumab in Healthy Japanese Adult Males: Results of a Randomized Trial.
    Morita J; Tanaka M; Nomoto M; Matsuki S; Tsuru T; Matsuguma K; Shiramoto M
    BioDrugs; 2016 Feb; 30(1):17-25. PubMed ID: 26691837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects.
    Hanes V; Chow V; Zhang N; Markus R
    Cancer Chemother Pharmacol; 2017 May; 79(5):881-888. PubMed ID: 28341959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subcutaneous Trastuzumab: A Review in HER2-Positive Breast Cancer.
    Heo YA; Syed YY
    Target Oncol; 2019 Dec; 14(6):749-758. PubMed ID: 31686307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.